International Community Health Services (ICHS) has launched Together We Rise, a wellness podcast with useful information ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. Shares were 9.5% higher ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Body positivity is shifting with the rise of weight-loss drugs and a booming skincare industry. Discover how body neutrality offers a healthier approach.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...